O‐25: Ledipasvir/Sofosbuvir single tablet regimen is highly effective treatment for patients with HCV genotype 2 infection

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|S2|15-15

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.S2, 2015-06, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 544-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

A different perspective on sofosbuvir‐ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital‐c network study

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 1, 2018-01 ,pp. : 56-62

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 205-208

John Wiley & Sons Inc

Access to resources Recommend Favorite

O‐28: Safety and efficacy of ledipasvir/sofosbuvir for the treatment of hepatitis c infection: interim analysis of a prospective, observational study

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 17-17

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite